although
risk
transfusiontransmit
infect
today
lower
ever
suppli
safe
blood
product
remain
subject
contamin
known
yet
identifi
human
pathogen
continu
improv
implement
donor
select
sensit
screen
test
effect
inactiv
procedur
ensur
elimin
least
reduct
risk
acquir
transfus
transmit
infect
addit
ongo
educ
uptod
inform
regard
infecti
agent
potenti
transmit
via
blood
compon
necessari
promot
report
advers
event
import
compon
transfus
transmit
diseas
surveil
thu
collabor
parti
involv
transfus
medicin
includ
nation
haemovigil
system
crucial
protect
secur
blood
product
suppli
known
emerg
bloodborn
pathogen
although
earli
report
histori
medicin
describ
attempt
treat
patient
human
anim
blood
product
transfus
medicin
rel
young
field
develop
sinc
second
half
last
centuri
rapidli
howev
becam
clear
therapeut
approach
also
carri
problem
compat
red
blood
cell
plasma
donor
recipi
possibl
transmit
infecti
diseas
past
risk
transfusiontransmit
infect
tti
accept
patient
physician
unavoid
lowrisk
blood
suppli
expect
today
sinc
earli
nineteen
sixti
blood
bank
well
plasma
manufactur
industri
aggress
pursu
strategi
reduc
risk
tti
particular
donor
exclus
criteria
histori
hepat
transfus
past
six
month
place
sinc
earli
today
donor
evalu
laboratori
screen
test
pathogen
inactiv
procedur
consid
crucial
tool
reduc
risk
tti
complet
elimin
risk
time
advanc
move
transfus
medicin
toward
increasingli
safer
product
steadili
escal
cost
thu
lead
major
differ
transfus
product
safeti
wealthi
poor
countri
current
effort
strategi
greatli
help
reduc
transfusionassoci
risk
inde
risk
infect
contamin
blood
unit
today
order
magnitud
lower
compar
thirti
year
ago
tabl
consider
portion
improv
due
introduct
nucleic
acid
test
nat
rather
reli
sole
measur
pathogenspecif
humor
immun
respons
donor
order
maintain
integr
puriti
adequaci
blood
suppli
new
donor
screen
assay
donor
deferr
pathogen
inactiv
blood
compon
need
balanc
undu
loss
potenti
donor
overli
stringent
exclus
criteria
effort
would
ideal
support
nation
intern
haemovigil
network
help
identifi
emerg
new
tti
threat
facilit
qualiti
assur
qualiti
control
abil
monitor
step
transfus
chain
figur
risk
bacteri
infect
emerg
major
caus
transfus
relat
morbid
mortal
part
due
reduct
risk
bacteri
contamin
frequent
platelet
concentr
plt
red
blood
compon
like
mani
microorgan
surviv
propag
storag
condit
typic
use
plt
less
rbc
consequ
increas
awar
clinic
relev
bacteri
contamin
blood
compon
aabb
formerli
american
associ
blood
bank
releas
standard
diminish
bacteri
tti
particular
bacteri
test
platelet
suggest
effect
measur
improv
transfus
safeti
three
test
system
licens
us
use
mani
transfus
center
around
world
screen
test
appear
quit
effect
recent
data
indic
frequenc
bacteri
contamin
declin
contamin
detect
one
apheresi
plt
concentr
test
estim
incid
rate
bacteri
tti
clinic
consequ
rang
one
transfus
plt
larg
depend
amount
bacteria
transfus
type
bacterium
pathogen
order
design
effect
strategi
reduc
bacteri
tti
bacteri
infect
frequent
divid
base
origin
microorgan
differenti
infect
origin
environ
skin
transfus
subject
like
deriv
donor
bacteremia
commonli
contamin
occur
blood
collect
insuffici
disinfect
venipunctur
site
handl
blood
product
leaki
seal
result
predomin
bacteria
isol
usual
commens
skin
gastrointestin
tract
flora
report
american
red
cross
detect
bacteri
contamina
tion
platelet
show
major
isol
gramposit
aerob
pathogen
nearli
line
organ
identifi
platelet
unit
implic
case
transfusionassoci
sepsi
gramposit
aerob
measur
reduc
risk
bacteri
contamin
focu
differ
step
transfus
chain
figur
classifi
six
aspect
donor
elig
reduc
asymptomat
donor
bacteremia
subject
recent
dental
treatment
minor
surgeri
increas
bodi
temperatur
present
exclud
donat
optim
product
process
handl
storag
continu
train
supervis
respons
personnel
donat
product
process
key
element
high
qualiti
standard
product
safeti
also
consist
storag
temperatur
rbc
plt
need
maintain
ensur
product
integr
skin
prepar
improv
donor
arm
disinfect
shown
crucial
reduc
number
remain
bacteria
phlebotomi
punctur
site
remov
initi
whole
blood
collect
divers
shown
remov
first
ml
whole
blood
collect
bag
might
reduc
contamin
risk
skin
bacteria
fact
improv
donor
arm
disinfect
associ
blood
divers
report
reduc
risk
bacteri
contamin
bacteri
detect
method
differ
method
investig
detect
bacteria
platelet
product
prior
transfus
includ
autom
bacteri
cultur
method
bactalert
system
direct
bacteri
stain
bacteri
endotoxin
ribosom
assay
nucleic
acid
test
bacteri
dna
measur
consumpt
co
product
pall
bd
pall
corpor
howev
none
detect
method
seem
identifi
bacteri
contamin
addit
bacteri
screen
test
well
better
time
bacteri
test
ie
closer
time
transfus
might
need
improv
likelihood
correctli
identifi
bacteri
contamin
blood
product
pathogen
reduct
method
pathogen
reduct
proactiv
approach
reduc
risk
tti
could
prove
effect
known
emerg
pathogen
goal
pathogen
inactiv
reduc
transmiss
pathogen
bacteria
virus
protozoa
without
compromis
therapeut
efficaci
blood
product
introduc
secondari
risk
techniqu
current
limit
discuss
detail
two
last
decad
much
attent
given
prevent
transfusiontransmit
viral
infect
human
cell
lymphotrop
viru
htlv
ii
hepat
c
viru
hcv
hepat
b
viru
hbv
west
nile
viru
wnv
given
potenti
transmiss
virus
immunolog
window
period
ie
period
earli
infect
immunolog
test
nonreact
novel
nonserolog
base
approach
viral
nucleic
acid
test
nat
establish
today
nat
perform
minipool
plasma
donat
significantli
increas
sensit
detect
infect
blood
compon
reveal
viral
agent
earlier
window
period
antibodi
antigen
assay
ever
limit
blood
compon
low
level
viremia
even
escap
detect
nat
despit
limit
combin
serolog
test
nat
consider
reduc
risk
viral
transmiss
blood
transfus
surveil
studi
europ
us
document
signific
reduct
risk
hcv
hiv
transmiss
blood
product
last
three
decad
mid
antihiv
serolog
test
introduc
follow
year
later
similar
approach
hcv
european
plasma
fraction
industri
introduc
viral
nat
method
ensur
integr
viru
interdict
new
screen
method
wide
introduc
mani
addit
countri
implement
viral
nat
test
greatli
help
reduc
residu
risk
viral
transmiss
window
period
reduc
time
effect
detect
day
sole
serolog
test
day
hiv
day
hcv
consequ
estim
risk
hiv
transmiss
date
hcv
per
million
unit
transfus
shown
recent
studi
assess
risk
transfusionmedi
hiv
hcv
infect
benefit
nat
test
antibodi
test
confirm
show
one
donat
test
posit
hcv
rna
antihcv
antibodi
hiv
appar
shorter
window
period
one
million
donat
rna
posit
antibodi
neg
howev
observ
nat
detect
rate
rel
benefit
vari
wide
site
instanc
europ
antihcv
antibodi
neg
hcv
rna
posit
sampl
identifi
among
million
donat
test
nat
yield
nat
reactiv
sampl
per
million
antibodi
neg
donat
compar
north
america
nat
yield
donat
pacif
area
nat
yield
donat
addit
nat
detect
rate
may
affect
viral
sequenc
polymorph
next
gener
nat
test
need
design
effect
cope
increas
global
viral
divers
especi
highli
variabl
pathogen
hiv
hcv
risk
tt
hbv
infect
continu
reduc
sinc
introduct
hepat
b
surfac
antigen
hbsag
test
earli
million
individu
infect
world
wide
hbv
remain
consider
risk
tt
infect
hbv
surfac
antigen
hbsag
main
screen
target
routin
includ
donor
screen
fail
detect
presenc
hbv
window
period
number
countri
also
ad
test
antibodi
direct
hbv
core
protein
antihbc
standard
screen
attempt
detect
chronic
viru
carrier
lowlevel
viremia
may
detect
hbsag
level
today
residu
risk
tt
hbv
infect
vari
per
million
blood
donat
australia
usa
canada
northern
europ
southern
europ
per
million
donat
hong
kong
larg
reflect
global
epidemiolog
hbv
even
though
present
regul
mandatori
test
blood
compon
hbv
nat
exist
number
countri
low
hbv
preval
implement
hbv
nat
test
plasma
pool
howev
evid
far
pool
test
hbv
nat
superior
sensit
test
hbsag
kinet
viral
antigen
antibodi
appear
hbv
infect
creat
two
differ
window
period
one
test
may
fail
earli
acut
phase
serolog
marker
still
neg
late
chronic
phase
hbsag
may
becom
gradual
undetect
although
infect
remain
thu
effect
immunolog
window
period
could
longer
gener
consid
median
day
nat
could
potenti
identifi
case
may
also
particular
benefit
detect
hbv
dna
occult
hbv
infect
hbv
dna
present
plasma
absenc
detect
hbsag
variabl
presenc
antihbc
antihb
antibodi
addit
case
infect
hbv
mutant
affect
surfac
antigen
conform
may
result
failur
detect
hbv
infect
routin
diagnost
assay
even
though
hbv
nat
could
detect
case
higher
level
sensit
nat
may
necessari
cope
characterist
low
level
viremia
iuml
seen
occult
hbv
infect
therefor
wnv
nat
usual
perform
singledon
level
locat
period
high
incid
infect
tt
wnv
case
describ
far
europ
blood
donat
test
posit
wnv
rna
among
test
sampl
netherland
fact
wnv
preval
quit
infrequ
europ
probabl
result
viral
strain
differ
herd
immun
rel
absenc
mosquito
transmit
viru
human
asid
hiv
hcv
hbv
wnv
number
viral
infect
transmit
transfus
blood
product
describ
even
though
associ
clinic
manifest
human
cell
lymphotrop
virus
ii
htlviii
associ
adult
cell
leukemia
htlvassoci
myelopathi
tropic
spastic
paraparesi
retrovirus
also
attribut
role
increas
risk
develop
sever
asthma
respiratori
urinari
tract
infect
uveiti
dermat
global
epidemiolog
htlv
vari
wide
preval
rate
certain
area
japan
countri
caribbean
subsaharan
africa
area
middl
east
south
america
transfusionassoci
transmiss
htlviii
occur
cellular
compon
infect
declin
compon
storag
particularli
day
risk
htlv
transmiss
us
low
million
case
htlvrelat
diseas
transfus
transmiss
rare
transfusionassoci
transmiss
human
herp
virus
includ
cytomegaloviru
cmv
human
herpesviru
also
known
kaposi
sarcomaassoci
herpesviru
describ
pose
signific
threat
especi
immunocompromis
subject
like
human
herp
virus
cellassoci
pathogen
cellular
compon
thu
main
compart
transmiss
transfus
blood
product
recommend
control
cmv
transmiss
suscept
group
establish
patient
increas
risk
cmv
diseas
receiv
cmvseroneg
andor
leucoreduc
product
latter
shown
reduc
risk
cmv
transmiss
consider
human
gammaherpesviru
caus
agent
kaposi
sarcoma
probabl
caus
multicentr
castleman
diseas
primari
effus
lymphoma
although
normal
transmit
saliva
sexual
contact
evid
transmit
via
blood
transfus
solid
organ
transplant
despit
evid
success
bloodborn
transmiss
data
exist
yet
link
tt
transmiss
diseas
immunocompet
subject
parvoviru
nonenvelop
erythroviru
infect
hematopoiet
cell
healthi
individu
infect
via
respiratori
rout
lead
erythema
infectiosum
fifth
diseas
usual
mild
selflimit
childhood
diseas
manifest
adult
fever
rash
myalgia
arthropathi
pregnant
women
transmit
infect
intrauterin
subsequ
fetal
heart
failur
hydrop
fetali
transfus
transmiss
mild
nonlifethreaten
symptom
even
immunocompromis
patient
report
sever
studi
epidemiolog
analys
found
recur
contamin
blood
product
sinc
viru
lack
envelop
resist
viru
inactiv
method
solvent
deterg
method
heat
inactiv
methylen
blue
europ
plasma
pool
use
product
antid
immunoglobulin
must
exceed
iu
per
millilit
novel
pcrbase
detect
quantif
kit
develop
end
last
year
two
virus
gener
associ
fecalor
transmiss
hepat
viru
hav
e
viru
hev
shown
least
occasion
transmiss
via
blood
transfus
pathogen
nonenvelop
rna
virus
low
preval
develop
countri
advanc
environment
hygien
vaccin
avail
hav
howev
hav
hev
transfusiontransmiss
report
mild
liver
diseas
result
viral
agent
hgv
hepat
g
viru
also
known
gb
viru
type
c
ttviru
sen
viru
shown
transmiss
blood
product
studi
conduct
germani
donat
screen
found
hgv
rna
posit
similarli
preval
ttv
among
healthi
blood
donor
widespread
especi
asia
preval
senv
healthi
individu
rang
usa
japan
howev
report
exist
link
transfusionassoci
transmiss
virus
clinic
symptom
procedur
protect
blood
suppli
pathogen
implement
asid
viral
pathogen
tt
relat
infect
less
well
document
number
potenti
tt
viral
threat
compar
inform
miss
among
coronaviru
sever
acut
respiratori
syndrom
sarscov
influenza
viru
avian
flu
seem
primarili
respiratori
mode
transmiss
evid
viremia
suggest
caution
bloodborn
transmiss
yet
conclus
rule
especi
sarscov
concern
potenti
risk
transfus
transmiss
led
global
implement
temporari
precautionari
measur
rel
risk
evalu
use
consid
length
asymptomat
virem
stage
infect
individu
virus
short
virem
episod
along
low
level
viremia
may
repres
rel
moder
risk
tti
case
wnv
parasit
common
infecti
agent
worldwid
sever
protozoan
shown
transmit
via
blood
transfus
malaria
endem
tropic
subtrop
region
africa
million
infect
one
million
death
annual
caus
one
four
speci
plasmodium
falciparum
vivax
malaria
oval
mosquitoborn
intraerythrocyt
parasit
infect
liver
red
blood
cell
rbc
caus
period
episod
fever
flulik
symptom
along
massiv
lysi
erythrocyt
risk
tt
malaria
differ
wide
lowendem
countri
infect
import
outsid
eg
travel
immigr
individu
highli
endem
region
region
high
preval
plasmodium
infect
gener
popul
latter
limit
data
avail
one
report
benin
show
one
third
screen
blood
donor
harbor
plasmodium
falciparum
trophozoit
potenti
abl
transmit
pathogen
blood
product
risk
lowendem
area
introduc
either
travel
immigr
high
endem
area
latter
usual
individu
protect
immun
statu
mani
year
infect
still
harbor
parasit
nevertheless
risk
transfusiontransmit
malaria
lowendem
area
like
europ
us
low
one
million
unit
transfus
potenti
infecti
european
countri
well
us
current
strategi
prevent
tt
malaria
base
risk
group
assess
includ
donor
deferr
month
visitor
lowendem
area
highendem
countri
year
perman
donor
histori
resid
endem
area
howev
deferr
polici
lead
extens
countri
unafford
loss
blood
donat
reason
combin
travelbas
risk
assess
serolog
screen
test
enzym
immunoassay
eia
immunofluoresc
antibodi
test
ifat
introduc
number
countri
trypanosoma
cruzi
etiolog
agent
chaga
diseas
cd
endem
central
south
america
part
mexico
acut
infect
accompani
acut
symptom
like
fever
lymphoadenomegali
hepatoand
spleenomegali
year
infect
patient
present
seriou
organ
enlarg
cardiomegali
occasion
megaesophagu
individu
endem
area
may
chronic
carrier
parasit
potenti
risk
transmit
parasit
via
transfus
blood
although
studi
perform
us
found
notic
seropreval
rate
among
risk
donor
bloodborn
cruzi
infect
infrequ
north
america
report
case
transfus
case
wellknown
mexico
central
south
america
mani
countri
serolog
test
perform
posit
donor
defer
recent
licensur
blood
donor
screen
test
test
shortli
start
us
parasit
implic
transfusionassoci
transmiss
tickborn
pathogen
babesia
microti
etiolog
agent
babesiosi
frequent
transfusiontransmit
parasit
babesia
microti
transmit
ixod
tick
lead
sever
complic
includ
hemolyt
anemia
thrombocytopenia
death
especi
transmit
immunocompromis
asplen
subject
studi
regard
transfusiontransmit
babesiosi
includ
report
fatal
diseas
outcom
case
known
us
sinc
babesia
intraerythrocyt
microb
leucoreduct
ineffect
approach
reduc
transmiss
risk
given
absenc
appropri
serolog
assay
pose
blood
safeti
risk
leishmania
donovani
transmit
primarili
bite
infect
sand
fli
also
shown
transmit
blood
caus
clinic
diseas
newborn
immunosuppress
subject
howev
case
appear
restrict
highli
endem
area
middl
east
pose
signific
risk
part
world
nevertheless
individu
return
us
combat
zone
iraq
current
defer
one
year
asid
parasit
tickborn
agent
two
bacteria
anaplasma
phagocytophilum
rickettsia
rickettsii
rare
found
blood
product
although
tt
tickborn
infect
larg
confin
northeastern
us
one
case
tt
babesia
infect
japan
variant
cjd
vcjd
human
form
bovin
spongiform
enceph
bse
howev
unlik
classic
creutzfeldtjacob
diseas
cjd
variant
cjd
vcjd
primarili
affect
peopl
year
age
like
transmit
consum
tissu
bseinfect
anim
although
initi
consid
bloodborn
prion
diseas
shown
anim
model
transmissi
blood
product
evid
bloodborn
transmiss
classic
cjd
still
lack
three
case
transfusiontransmit
vcjd
report
uk
three
report
blood
donor
develop
clinicalappar
vcjd
blood
donat
two
recipi
show
sign
clinic
diseas
wherea
third
patient
asymptomat
detect
prion
time
death
unrel
caus
notabl
three
infect
patient
receiv
nonleucodeplet
red
blood
cell
despit
fact
date
tt
vcjd
case
associ
use
plasma
product
one
import
factor
estim
risk
tt
prion
diseas
may
pose
futur
potenti
prolong
preclin
carrier
state
last
decad
thu
repres
signific
risk
transfusionmedicin
least
region
england
ireland
franc
mani
case
vcjd
report
countermeasur
franc
uk
adopt
practic
declin
individu
receiv
transfus
blood
compon
sinc
indefinit
similarli
us
donor
histori
extend
resid
uk
europ
histori
transfus
uk
perman
refus
concept
pathogen
inactiv
blood
compon
reduc
residu
risk
known
pathogen
effect
elimin
new
yet
unknown
pathogen
howev
differ
approach
increas
blood
safeti
without
compromis
product
efficaci
caus
advers
effect
toxic
mutagen
chemic
may
use
process
number
pathogen
reduct
method
employ
europ
none
current
avail
us
choic
pathogen
reduct
approach
depend
whether
use
treat
compon
transfus
rbc
plt
plasma
product
manufactur
plasma
europ
two
distinct
method
methylen
blue
mb
solventdeterg
sd
current
employ
treatment
plasma
intend
transfus
mb
phenothiazin
color
inactiv
virus
bacteria
exposur
visibl
light
advantag
use
singl
plasma
unit
ineffect
intracellular
pathogen
probabl
interact
coagul
factor
consider
reduc
efficaci
sd
approach
act
disrupt
envelop
protein
target
pathogen
thu
compromis
integr
pathogen
render
noninfecti
approach
use
small
pool
plasma
limit
techniqu
activ
nonenvelop
pathogen
level
coagul
factor
protein
may
decreas
significantli
sd
treatment
method
amotosalen
hcl
synthet
psoralen
combin
exposur
ultraviolet
uva
light
caus
perman
crosslink
bacteri
viral
nucleic
acid
chain
therebi
stop
pathogen
replic
photochem
treatment
pct
amotosalen
uva
light
use
ffp
platelet
commerci
product
base
approach
intercept
system
introduc
clinic
practic
europ
year
ago
complet
phase
iii
trial
usa
extens
studi
shown
approach
effect
pathogen
current
screen
includ
envelop
nonenvelop
virus
bacteria
gramposit
neg
protozoan
cruzi
plasmodium
falciparum
howev
larg
control
studi
indic
pct
may
neg
effect
function
platelet
transfus
use
treat
platelet
prepar
repeat
shorter
interv
use
untreat
platelet
prepar
asid
approach
pathogen
reduct
platelet
prepar
least
three
techniqu
pathogen
inactiv
rbc
current
develop
synthet
alkyl
agent
compound
frangibl
anchorlink
effector
frale
class
capabl
disrupt
pathogen
rna
dna
inactin
binari
ethyleneimin
bind
nucleic
acid
result
inhibit
pathogen
replic
riboflavin
vitamin
b
natur
occur
nutrient
even
though
agent
enter
phase
iii
clinic
trial
none
offici
approv
time
review
written
approach
well
newli
develop
one
need
show
convincingli
success
elimin
target
pathogen
maintain
blood
product
qualiti
addit
possibl
limit
high
cost
longterm
side
effect
addit
inabl
inactiv
certain
pathogen
like
sporeform
bacteria
need
overcom
ensur
pathogenfre
blood
product
larg
scale
afford
price
gener
public
may
idealist
belief
riskfre
blood
product
achiev
today
world
fact
threat
infecti
agent
enter
blood
suppli
static
may
evolv
new
pathogen
emerg
old
one
chang
epidemiolog
pattern
nevertheless
goal
safe
afford
blood
suppli
meet
grow
global
demand
may
reach
coordin
optim
step
transfus
chain
includ
care
consider
donor
elig
criteria
adher
rigor
rule
donat
process
storag
optim
implement
avail
screen
test
use
suitabl
pathogen
inactiv
method
final
vigil
prudent
physician
evalu
necess
transfus
effort
invest
provid
lowest
possibl
risk
blood
product
need
match
dilig
physician
administ
transfus
need
report
advers
consequ
blood
transfus
henc
nation
haemovigil
system
link
intern
network
becom
indispens
element
blood
product
safeti
qualiti
combin
develop
implement
sensit
afford
detect
inactiv
approach
measur
make
blood
transfus
safer
form
therapi
even
place
risk
date
consid
signific
